1,417 Shares in Becton, Dickinson and Company $BDX Acquired by Hilltop National Bank

Key Points

• Hilltop National Bank acquired 1,417 shares of Becton, Dickinson and Company (BDX), valued at approximately $244,000, marking a new position in the medical instruments supplier during Q2.
• Becton, Dickinson reported $3.68 EPS for its last quarter, exceeding analysts' expectations of $3.40, with a revenue increase of 10.4% year-over-year.
• The company has announced a quarterly dividend of $1.04, representing a 2.1% yield, with a payout ratio currently at 74.82%.

Hilltop National Bank bought a new position in Becton, Dickinson and Company (NYSE:BDX - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 1,417 shares of the medical instruments supplier's stock, valued at approximately $244,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC raised its holdings in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after purchasing an additional 877 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of Becton, Dickinson and Company by 50.6% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock worth $18,808,000 after acquiring an additional 27,581 shares in the last quarter. FORA Capital LLC purchased a new position in shares of Becton, Dickinson and Company in the first quarter worth approximately $3,458,000. Foster Victor Wealth Advisors LLC purchased a new position in shares of Becton, Dickinson and Company in the first quarter worth approximately $6,406,000. Finally, GAMMA Investing LLC increased its position in shares of Becton, Dickinson and Company by 29.9% in the first quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock worth $744,000 after acquiring an additional 748 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $193.67 on Friday. The company's 50 day moving average price is $189.03 and its 200 day moving average price is $187.68. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The company has a market capitalization of $55.51 billion, a PE ratio of 34.83, a PEG ratio of 1.50 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. The firm had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm's revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the firm posted $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were given a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company's payout ratio is currently 74.82%.

Analyst Ratings Changes

Several research analysts have recently weighed in on BDX shares. Argus lifted their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Wells Fargo & Company lifted their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research report on Friday, August 8th. Piper Sandler reissued a "neutral" rating and issued a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Weiss Ratings reissued a "hold (c-)" rating on shares of Becton, Dickinson and Company in a research report on Saturday, September 27th. Finally, Morgan Stanley boosted their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Three equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $205.40.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the business's stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares of the company's stock, valued at $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares of the company's stock, valued at $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,023 shares of company stock valued at $562,036 over the last three months. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.